Bisphosphonate Use After Hip Fracture in Older Adults : A Nationwide Retrospective Cohort Study
(2017) In Journal of the American Medical Directors Association 18(6). p.515-521- Abstract
Objectives: The aim of this study was to investigate the association between bisphosphonate use and the risk of new fracture in a nationwide cohort of individuals with previous hip fractures, with emphasis on individuals above 80 years of age. Design, setting, and participants: From a nationwide cohort with hip fracture (2006-2012) (n = 93, 601), each individual prescribed bisphosphonates after hip fracture (n = 5845) was matched with up to three individuals not prescribed bisphosphonates, resulting in a cohort of 21,363 individuals. Main outcome measure: A new hip fracture. Results: During a mean follow-up period of 2.98 (range, 0.02-8) years, 4581 fractures occurred in the cohort. Before the initiation of bisphosphonate therapy,... (More)
Objectives: The aim of this study was to investigate the association between bisphosphonate use and the risk of new fracture in a nationwide cohort of individuals with previous hip fractures, with emphasis on individuals above 80 years of age. Design, setting, and participants: From a nationwide cohort with hip fracture (2006-2012) (n = 93, 601), each individual prescribed bisphosphonates after hip fracture (n = 5845) was matched with up to three individuals not prescribed bisphosphonates, resulting in a cohort of 21,363 individuals. Main outcome measure: A new hip fracture. Results: During a mean follow-up period of 2.98 (range, 0.02-8) years, 4581 fractures occurred in the cohort. Before the initiation of bisphosphonate therapy, individuals later prescribed bisphosphonates had an increased risk of hip fracture (multivariable adjusted odds ratio [OR], 2.63; 95% confidence interval [CI], 2.23-3.24) compared with controls. In the period after bisphosphonate therapy initiation, individuals prescribed bisphosphonates had a lower risk of hip fracture (multivariable adjusted hazard ratio [HR], 0.76; 95% CI, 0.65-0.90) compared with controls. Similar effects were seen after the initiation of bisphosphonates in individuals aged more than 80 years (HR, 0.79; 95% CI, 0.62-0.99). In contrast, the initiation of bisphosphonate therapy did not influence the risk of injurious falls not resulting in fracture (HR, 0.95; 95% CI, 0.86-1.05). Conclusion: Bisphosphonate use was associated with a decreased risk of hip fracture in this nationwide cohort of older men and women, with similar risk reductions in individuals older than 80 years.
(Less)
- author
- Nordström, Peter ; Toots, Annika ; Gustafson, Yngve ; Thorngren, Karl Göran LU ; Hommel, Ami LU and Nordström, Anna
- organization
- publishing date
- 2017
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Bisphosphonates, Cohort study, Hip fractures, Older individuals
- in
- Journal of the American Medical Directors Association
- volume
- 18
- issue
- 6
- pages
- 515 - 521
- publisher
- Elsevier
- external identifiers
-
- scopus:85013414268
- pmid:28238673
- wos:000402431200009
- ISSN
- 1525-8610
- DOI
- 10.1016/j.jamda.2016.12.083
- language
- English
- LU publication?
- yes
- id
- ad8464ad-515b-48c4-836c-4b84aed8bc17
- date added to LUP
- 2017-03-16 08:18:52
- date last changed
- 2024-05-12 10:20:19
@article{ad8464ad-515b-48c4-836c-4b84aed8bc17,
abstract = {{<p>Objectives: The aim of this study was to investigate the association between bisphosphonate use and the risk of new fracture in a nationwide cohort of individuals with previous hip fractures, with emphasis on individuals above 80 years of age. Design, setting, and participants: From a nationwide cohort with hip fracture (2006-2012) (n = 93, 601), each individual prescribed bisphosphonates after hip fracture (n = 5845) was matched with up to three individuals not prescribed bisphosphonates, resulting in a cohort of 21,363 individuals. Main outcome measure: A new hip fracture. Results: During a mean follow-up period of 2.98 (range, 0.02-8) years, 4581 fractures occurred in the cohort. Before the initiation of bisphosphonate therapy, individuals later prescribed bisphosphonates had an increased risk of hip fracture (multivariable adjusted odds ratio [OR], 2.63; 95% confidence interval [CI], 2.23-3.24) compared with controls. In the period after bisphosphonate therapy initiation, individuals prescribed bisphosphonates had a lower risk of hip fracture (multivariable adjusted hazard ratio [HR], 0.76; 95% CI, 0.65-0.90) compared with controls. Similar effects were seen after the initiation of bisphosphonates in individuals aged more than 80 years (HR, 0.79; 95% CI, 0.62-0.99). In contrast, the initiation of bisphosphonate therapy did not influence the risk of injurious falls not resulting in fracture (HR, 0.95; 95% CI, 0.86-1.05). Conclusion: Bisphosphonate use was associated with a decreased risk of hip fracture in this nationwide cohort of older men and women, with similar risk reductions in individuals older than 80 years.</p>}},
author = {{Nordström, Peter and Toots, Annika and Gustafson, Yngve and Thorngren, Karl Göran and Hommel, Ami and Nordström, Anna}},
issn = {{1525-8610}},
keywords = {{Bisphosphonates; Cohort study; Hip fractures; Older individuals}},
language = {{eng}},
number = {{6}},
pages = {{515--521}},
publisher = {{Elsevier}},
series = {{Journal of the American Medical Directors Association}},
title = {{Bisphosphonate Use After Hip Fracture in Older Adults : A Nationwide Retrospective Cohort Study}},
url = {{http://dx.doi.org/10.1016/j.jamda.2016.12.083}},
doi = {{10.1016/j.jamda.2016.12.083}},
volume = {{18}},
year = {{2017}},
}